Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.34 |
| ▸ | ACE | P12821 | 3/20 | 0.34 |
| ▸ | REN | P00797 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26724258 | 0.88 | CHRM3 (0.44) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL26999903 | 0.85 | CHRM3 (0.45) | CHRM3FFAR1ACERENCHRNB2 | |
| SCHEMBL26997773 | 0.85 | CHRM3 (0.42) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL26999907 | 0.85 | CHRM3 (0.45) | CHRM3L3MBTL1GLP1RPOLB | |
| SCHEMBL26208260 | 0.85 | CHRM3 (0.45) | CHRM3FFAR1ACERENCHRNB2 | |
| SCHEMBL26208264 | 0.82 | CHRM3 (0.43) | CHRM3ACERENCHRNB2CHRNA5 | |
| SCHEMBL26999914 | 0.81 | CHRM3 (0.42) | CHRM3ACEREN | |
| SCHEMBL26205578 | 0.81 | CHRM3 (0.41) | CHRM3ACERENRAB9A | |
| SCHEMBL26727407 | 0.81 | CHRM3 (0.41) | CHRM3ACERENRAB9A | |
| SCHEMBL13929717 | 0.79 | CHRNB2 (0.52) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRM3 179/4885FFAR1 1846/4885ACE 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.